Overview of IV associated Influenza B

ID Literature Title Group
1 28465552 A reassortant H9N2 influenza virus containing 2009 pandemic H1N1 internal-protein genes acquired enhanced pig-to-pig transmission after serial passages in swine
Mutation
2 25339773 Virulence determinants in the PB2 gene of a mouse-adapted H9N2 virus
Mutation
3 19946717 Readaptation of a low-virulence influenza H9 escape mutant in mice: the role of changes in hemagglutinin as revealed by site-specific mutagenesis
Mutation
4 21849466 Reversion of PB2-627E to -627K during replication of an H5N1 Clade 2.2 virus in mammalian hosts depends on the origin of the nucleoprotein
Mutation
5 23199027 Sequence and phylogenetic analysis of highly pathogenic avian influenza H5N1 viruses isolated during 2006-2008 outbreaks in Pakistan reveals genetic diversity
Mutation
6 16479508 Recovery of drug-resistant influenza virus from immunocompromised patients: a case series
Mutation
7 23335741 Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza
Mutation
8 30349332 Antiviral resistance markers in influenza virus sequences in Mexico, 2000-2017
Mutation
9 29409570 Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
Mutation
10 39597751 Antigenic Divergence from the Seasonal Vaccine of the Influenza Virus Strains Circulating in Romania During Three Successive Seasons (2021-2024)
Mutation
11 39557155 Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season
Mutation
12 33568453 Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase
Mutation
13 16912325 Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses
Mutation
14 21994620 Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective
Mutation
15 24279698 Genetic mutations in influenza H3N2 viruses from a 2012 epidemic in Southern China
Mutation
16 25609803 Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice
Mutation
17 27849220 Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient
Mutation
18 29489060 Molecular genetic characteristics of influenza A virus clinically isolated during 2011-2016 influenza seasons in Korea
Mutation
19 30548432 Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan
Mutation
20 32004620 Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018
Mutation
21 25721488 Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014
Mutation
22 22848649 Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses
Mutation
23 39802823 Comprehensive molecular epidemiology of influenza viruses in Brazil: insights from a nationwide analysis
Mutation
24 28132927 Antigenic and genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016 season
Mutation
25 32064779 Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
Mutation
26 29145498 Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins
Mutation
27 20592084 Adaptation of pandemic H1N1 influenza viruses in mice
Mutation
28 21698272 Genomic polymorphism of the pandemic A (H1N1) influenza viruses correlates with viral replication, virulence, and pathogenicity in vitro and in vivo
Mutation
29 35446141 Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies
Mutation
30 23251479 Whole genome characterization, phylogenetic and genome signature analysis of human pandemic H1N1 virus in Thailand, 2009-2012
Mutation
31 26453960 A PB1 T296R substitution enhance polymerase activity and confer a virulent phenotype to a 2009 pandemic H1N1 influenza virus in mice
Mutation
32 20976194 Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype?
Mutation
33 20522774 Permissive secondary mutations enable the evolution of influenza oseltamivir resistance
Mutation
34 21470455 H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients
Mutation
35 22811535 Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation
Mutation
36 22970161 Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study
Mutation
37 25297528 Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses
Mutation
38 31697721 Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza
Mutation
39 26345289 Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility
Mutation
40 20205961 Circulation of human influenza viruses and emergence of Oseltamivir-resistant A(H1N1) viruses in Cameroon, Central Africa
Mutation
41 25297358 Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011
Mutation
42 20345239 Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts
Mutation
43 21470465 Drug-resistant pandemic (H1N1) 2009, South Korea
Mutation
44 22013054 Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses
Mutation
45 23442314 Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal
Mutation
46 28814737 Susceptibility of influenza A(H1N1)/pdm2009, seasonal A(H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014
Mutation
47 30971204 Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017
Mutation
48 31356626 Severe cases of seasonal influenza in Russia in 2017-2018
Mutation
49 32256457 Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors
Mutation
50 28802866 Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016
Mutation
51 22328930 Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10
Mutation
52 23369604 A (H1N1) pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico
Mutation
53 23927713 A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection
Mutation
54 21799795 A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase
Mutation
55 23930018 Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus
Mutation
56 25340711 Epidemiological and virological characteristics of influenza viruses circulating in Cambodia from 2009 to 2011
Mutation
57 39296541 Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas
Mutation
58 32547518 Characterization of Influenza A and B Viruses Circulating in Southern China During the 2017-2018 Season
Mutation
59 29941893 Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
Mutation
60 31538644 Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
Mutation
61 29023600 Reduced accumulation of defective viral genomes contributes to severe outcome in influenza virus infected patients
Mutation
62 39037444 Structure and dynamics of the proton-selective histidine and the gating tryptophan in an inward rectifying hybrid influenza B and A virus M2 proton channel
Mutation
63 18191435 A cluster of conserved basic amino acids near the C-terminus of the PB1 subunit of the influenza virus RNA polymerase is involved in the regulation of viral transcription
Mutation
64 29691337 Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
Mutation
65 12821478 Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir
Mutation
66 39659606 Molecular dynamics study on the effect of the N1 neuraminidase double mutant G147R/H274Y on oseltamivir sensitivity
Mutation
67 27486041 Discovery of Potential, Non-Toxic Influenza Virus Inhibitor by Computational Techniques
Mutation
68 30165308 Selection of influenza virus resistant to the novel camphor-based antiviral camphecene results in loss of pathogenicity
Mutation
69 11709315 Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
Mutation
70 23575174 Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season
Mutation
71 12574276 Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network
Mutation
72 25043638 Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013
Mutation
73 21306576 Influenza and other respiratory viruses in three Central American countries
Mutation
74 23917311 Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens
Mutation
75 37404185 Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility
Mutation
76 34388979 Use of hemagglutinin and neuraminidase amplicon-based high-throughput sequencing with variant analysis to detect co-infection and resolve identical consensus sequences of seasonal influenza in a university setting
Mutation
77 39593174 Genomic surveillance and evolutionary dynamics of influenza a virus in Sri Lanka
Mutation
78 39248230 Molecular characterisation of influenza B virus from the 2017/18 season in primary models of the human lung reveals improved adaptation to the lower respiratory tract
Mutation
79 34070388 Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018-2019
Mutation
80 19091818 Cocirculation of antigenic variants and the vaccine-type virus during the 2004-2005 influenza B virus epidemics in Japan
Mutation
81 23289789 Genetic analysis of influenza B viruses isolated in Uganda during the 2009-2010 seasons
Mutation
82 24734292 Peramivir and laninamivir susceptibility of circulating influenza A and B viruses
Mutation
83 31955521 Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons
Mutation
84 31323237 The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors
Mutation
85 27089319 The Molecular Epidemiology and Evolutionary Dynamics of Influenza B Virus in Two Italian Regions during 2010-2015: The Experience of Sicily and Liguria
Mutation
86 25691568 The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism
Mutation
87 34358217 Mutation E48K in PB1 Polymerase Subunit Improves Stability of a Candidate Live Attenuated Influenza B Virus Vaccine
Mutation
88 26044768 A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase
Mutation
89 29643248 A Single Amino Acid in the Polymerase Acidic Protein Determines the Pathogenicity of Influenza B Viruses
Mutation
90 16641465 Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient
Mutation
91 23267831 Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir
Mutation
92 30439983 Influenza B viruses circulated during last 5 years in Mongolia
Mutation
93 30574137 Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
Mutation
94 30792414 Molecular evolution of influenza B virus during 2011-2017 in Chaoyang, Beijing, suggesting the free influenza vaccine policy
Mutation
95 18408016 Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus
Mutation
96 26313754 Epidemiological and Evolutionary Dynamics of Influenza B Viruses in Malaysia, 2012-2014
Mutation
97 9874196 Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design
Mutation
98 20195900 Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors
Mutation
99 20695427 Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses
Mutation
100 21048522 Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer
Mutation
101 22535992 Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient
Mutation
102 23131559 A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs
Mutation
103 23529501 Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs
Mutation
104 24140051 A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains
Mutation
105 24795482 A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses
Mutation
106 25673705 Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium
Mutation
107 25786478 Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility
Mutation
108 29324781 Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015
Mutation
109 16081981 Variation of the conserved neutralizing epitope in influenza B virus victoria group isolates in Japan
Mutation
110 39233140 Antigenic analysis of the influenza B virus hemagglutinin protein
Mutation
111 37317069 Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs
Mutation
112 34696325 Cell-Adapted Mutations and Antigenic Diversity of Influenza B Viruses in Missouri, 2019-2020 Season
Mutation
113 36145480 Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid
Mutation